A phase III trial (NCT02017340) testing the efficacy and safety of nilvadipine (29) in participants with mild to moderate AD indicated that, while the drug demonstrated good safety, it did not show significant benefits in slowing cognitive decline in AD patients.477 Pioglitazone (30) is a PPARγ agonist widely used in the treatment of T2D.478 Two phase III clinical trials (NCT01931566 and NCT02284906) assessed the safety and efficacy of the drug in participants with AD-induced MCI but were terminated due to insufficient efficacy. This evidence concerns the gene PPARG and Alzheimer disease.